title: EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model.
abstract: OBJECTIVE
  Development of EGF-liposomes (LP-EGF) for selective molecules delivery in tumors expressing EGFR.
  
  
  METHODS
  In vitro cellular interaction of EGF-LP and nontargeted liposomes (LP-N) was assayed at 37 and 4 °C in cells expressing different EGFR levels. Receptor-mediated uptake was investigated by competition with a monoclonal antibody anti-EGFR. Selective intracellular drug delivery and efficacy was tested by oxaliplatin encapsulation. In vivo biodistribution of LP-N and LP-EGF was done in xenograft model.
  
  
  RESULTS
  LP-EGF was internalized by an active and selective mechanism through EGFR without receptor activation. Oxaliplatin LP-EGF decreased IC50 between 48 and 13% in cell EGFR+. LP-EGF was accumulated in tumor over 72 h postdosing, while LP-N in spleen.
  
  
  CONCLUSIONS
  LP-EGF represents an attractive nanosystem for cancer therapy or diagnosis.
authors.affiliation: Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain.|Innovative Targeting, Laboratory Experimental Surgical Oncology, Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Sara
authors.initials: S
authors.lastname: Zalba
authors.affiliation: Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain.
authors.forename: Ana Margarita
authors.initials: AM
authors.lastname: Contreras
authors.affiliation: Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Merino
authors.affiliation: Department of Chemistry & Edaphology, University of Navarra, Pamplona, Spain.
authors.forename: Iñigo
authors.initials: I
authors.lastname: Navarro
authors.affiliation: Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain.
authors.forename: Conchita Tros
authors.initials: CT
authors.lastname: de Ilarduya
authors.affiliation: Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain.
authors.forename: Iñaki F
authors.initials: IF
authors.lastname: Trocóniz
authors.affiliation: Innovative Targeting, Laboratory Experimental Surgical Oncology, Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Gerben
authors.initials: G
authors.lastname: Koning
authors.affiliation: Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain.
authors.forename: María J
authors.initials: MJ
authors.lastname: Garrido
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016503:Drug Delivery Systems; D004815:Epidermal Growth Factor / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry; D051379:Mice; D058990:Molecular Targeted Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000737:chemistry; D000077150:Oxaliplatin; D023041:Xenograft Model Antitumor Assays
chemical_list: D008081:Liposomes; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D004815:Epidermal Growth Factor; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGF; EGFR; cetuximab; colorectal cancer; oxaliplatin; targeted liposomes